Monday, 31 August 2026European Markets

ACTEOS Stock Over 15% Down So Far On Tuesday

Loading stream...

acteos (cac 40: eos.pa), a french supply chain management software firm, experienced an unexpected drop of 15.82% tuesday. this came as quite an eye-opener as only 0.71% had declined on its index (to eur7,444.77) indicating bearish signs in the market.

analysis of acteos's market performance

acteos' last closing price of eur1.58 marked an 18.56% decline from its 52-week high of eur1.94. it is evident that acteos isn't immune to market volatility as its intraday variation varied between 0.44% and 2.02% in each of its last week, month and quarter periods; with average volatility peaking at 1.52% per week/month/quarter respectively reflecting its uncertain fate. additionally, the company reported an earnings per share (eps) value of eur-0.05 over its last twelve month financial period, reflecting losses in profitability.

market sentiments and acteos's performance

acteos's steep drop could be explained by both its financial performance and overall market sentiment, such as investor reservations about profitability. furthermore, global economic malaise could further erode stock values further.

about acteos

acteos was established in 1986 and offers an array of services such as its acteos suite, mobility solutions, software-as-a-service offerings, hotline assistance, technical project management, technical project consulting and project consulting throughout france, germany and lebanon.

more news about acteos (eos.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com